Crinetics Pharmaceuticals, Inc.
CRNX
$37.48
$0.571.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2,873.41% | -- | -- | 158.40% | -43.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,873.41% | -- | -- | 158.40% | -43.59% |
| Cost of Revenue | 31.53% | 29.39% | 46.13% | 37.63% | 42.93% |
| Gross Profit | -18.01% | -20.13% | -45.90% | -36.80% | -43.98% |
| SG&A Expenses | 43.08% | 90.56% | 101.86% | 100.67% | 70.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.20% | 47.58% | 62.57% | 56.46% | 50.69% |
| Operating Income | -26.01% | -41.08% | -62.40% | -55.96% | -51.51% |
| Income Before Tax | -32.11% | -52.16% | -69.33% | -56.15% | -44.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -32.11% | -52.39% | -69.33% | -56.15% | -44.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.11% | -52.39% | -69.33% | -56.15% | -44.59% |
| EBIT | -26.01% | -41.08% | -62.40% | -55.96% | -51.51% |
| EBITDA | -26.01% | -41.21% | -62.68% | -56.23% | -51.23% |
| EPS Basic | -18.15% | -46.61% | -43.94% | -31.54% | -12.26% |
| Normalized Basic EPS | -18.15% | -46.41% | -43.95% | -31.55% | -12.27% |
| EPS Diluted | -18.15% | -46.61% | -43.94% | -31.54% | -12.26% |
| Normalized Diluted EPS | -18.15% | -46.41% | -43.95% | -31.55% | -12.27% |
| Average Basic Shares Outstanding | 11.81% | 3.94% | 17.63% | 18.71% | 28.79% |
| Average Diluted Shares Outstanding | 11.81% | 3.94% | 17.63% | 18.71% | 28.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |